CLL stands for chronic lymphocytic leukemia. It is a blood and bone marrow cancer that involves abnormal B lymphocytes (a type of white blood cell). CLL is commonly discussed in hematology-oncology clinics, cancer centers, and lab reports. It may be found during routine blood tests or after evaluation of symptoms such as swollen lymph nodes or fatigue.

Chronic lymphocytic leukemia is a blood cancer that starts in certain white blood cells called lymphocytes. It most often involves B lymphocytes, a type of immune cell that normally helps fight infection. It is called “chronic” because it often develops and progresses more slowly than acute leukemias. The term is commonly used in hematology-oncology clinics, cancer centers, and pathology reports to describe this specific leukemia subtype.

AML stands for acute myeloid leukemia, a cancer of the blood and bone marrow. It starts when immature myeloid cells (“blasts”) grow and build up, crowding out normal blood-forming cells. AML is commonly used as a diagnosis in hematology-oncology to explain symptoms like low blood counts and infection risk. It is also used to guide testing, risk classification, and treatment planning.

Acute myeloid leukemia is a fast-growing cancer of the blood and bone marrow. It starts in early blood-forming cells that normally develop into healthy white blood cells. It is commonly used as a diagnosis in hematology and oncology to guide urgent evaluation and treatment. It is also used in pathology and laboratory medicine to classify leukemia based on cell type and genetic features.

ALL most commonly refers to **acute lymphoblastic leukemia**. It is a **fast-growing (acute) blood and bone marrow cancer** that starts in early (immature) lymphoid cells. ALL is commonly discussed in **hematology-oncology** and **pediatric oncology**, but it can occur in adults too. Care for ALL often involves **systemic therapy** (treatment that reaches the whole body) plus structured follow-up.

Acute lymphoblastic leukemia is a fast-growing cancer of the blood and bone marrow. It starts when immature white blood cells called lymphoblasts multiply out of control. It is commonly discussed in hematology-oncology clinics, emergency care, and inpatient cancer units. The term is used in diagnosis, treatment planning, and follow-up of leukemia care.

Carcinomatous meningitis is a cancer complication where malignant cells spread to the membranes covering the brain and spinal cord. These membranes are called the meninges, and the involved layers are often referred to as the leptomeninges. It is most commonly discussed in oncology, neurology, and radiation oncology when new neurologic symptoms appear in someone with cancer. The term is used to describe a diagnosis, not a single treatment.

Leptomeningeal disease is cancer involvement of the thin membranes covering the brain and spinal cord. It occurs when tumor cells spread into the cerebrospinal fluid (CSF) and coat these membranes. It is most often discussed in advanced cancer care and neuro-oncology. It can affect both symptoms and treatment planning because the CSF circulates throughout the central nervous system.

Peritoneal carcinomatosis is cancer spread to the peritoneum, the thin lining that covers the inside of the abdomen and many abdominal organs. It usually means tumor cells have seeded across peritoneal surfaces rather than forming one single, contained mass. The term is commonly used in oncology imaging reports, surgical notes, and staging discussions. It helps clinicians describe disease extent and plan treatment and supportive care.

CUP stands for **cancer of unknown primary**. It means cancer is found in the body, but the place where it started (the **primary site**) is not identified after a standard evaluation. CUP is most often diagnosed when cancer is discovered as **metastatic disease** (spread to lymph nodes or other organs). The term is commonly used by oncology teams in pathology reports, imaging summaries, and treatment planning.